ABT News 43.38 09/18/2014 04:22:39 Abbott Laboratories (ABT)
Post# of 273322
Posted On: 09/18/2014 5:22:35 AM
Abbott Laboratories (ABT) 43.38 $ABT
Jim Cramer's 'Mad Money' Recap: Hooray for the Federal Reserve
at The Street - Wed Sep 17, 7:08PM CDT
Now that the Fed has done the right thing on monetary policy, investors should stop worrying and start thinking about how to make more money, Cramer says.
Look for Shares of Abbott Laboratories to Potentially Pullback after Yesterday's 1.12% Rise
Comtex SmarTrend(R) - Wed Sep 17, 4:27PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $42.76 to a high of $43.57. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $42.97 on volume of 4.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Abbott Labs (ABT) to Initiate New Trial on Absorb - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 4:05PM CDT
Abbott Labs (ABT) recently announced that it will initiate a trial, ABSORB IV, on bioresorbable vascular scaffold (BVS) Absorb.
Global Hemoglobin A1c Testing Devices (Laboratory Testing Devices & POC testing Devices) Market Analysis 2013-2019
M2 - Wed Sep 17, 3:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjh9n8/hemoglobin_a1c) has announced the addition of the "Hemoglobin A1c Testing Devices Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. 'Testing the levels of glycated hemoglobin provides an assurance to the healthcare practitioner about the patient's blood glucose level. This test can be used for diagnosis and monitoring of hemoglobin A1c levels in diabetic patients. Since A1C test reflects the average amount of glucose for the past 2 to 3 months, it is opined to be more reliable than conventional blood glucose test. Physicians are increasingly prescribing HbA1c test to their patients which will lead to an increase in the test volume. Moreover, rising diabetes incidence rate is a major driver for the HbA1c testing market. With growing awareness about prevention and management of diabetes, the demand for HbA1c testing devices will rise rapidly especially in the Asia-Pacific, Latin America, MiddleEast and African regions. Moreover, advent of these devices for the diagnosis of diabetes will further bolster the demand for these devices in future. For instance, approval for the COBAS INTEGRA 800 Tina-quant HbA1cDx assay, in 2013and Abbott's ARCHITECT Clinical Chemistry Hemoglobin A1c (HbA1c) test approved in 2014 for the diagnosis of diabetes were the major steps in the hemoglobin A1c testing industry. With this diagnostic tools, physicians can combat the rising incidence of diabetes with timely and appropriate actions in identifying and managing diabetes. Based on the end-use, the global hemoglobin A1c testing devices market is categorized into two segments namely laboratory testing and point-of-care (POC) testing devices. Laboratory testing devices held the majority share of the market in 2012, while the global market for point-of-care testing devices is expected to grow at a faster paceduring the forecast period. Based on technologies, the hemoglobin A1c testing devices market is further categorized into five segments, namely, ion-exchange HPLC, immunoassay, boronate affinity chromatography, direct enzymatic assay and others. The boronate affinity chromatography market will be growing at a faster pace during the forecast period as this technology has no interference from hemoglobin variants and is also used in both laboratory as well as point-of-care testing. Healthcare practitioners are recommending the use of devices which offer least variant interference and this would elevate the demand for boronate affinity chromatography in HbA1c testing. The global hemoglobin A1c testing devices market is categorized into the following segments: Hemoglobin A1cTesting Devices Market, by End-use - Laboratory Testing Devices - Point-of-Care (POC)Testing Devices Hemoglobin A1cTesting Devices Market, by Technology - Ion-Exchange High Performance Liquid Chromatography (HPLC) - Immunoassay - Boronate Affinity Chromatography - Direct Enzymatic Assay - Others (Micro-Optical Detection Method and Capillary Electrophoresis) Key Topics Covered: - Introduction - Executive Summary - Global Hemoglobin A1c Testing Devices Market Overview - Global Hemoglobin A1c Testing Devices Market, by End-Use - Global Hemoglobin A1c Testing Devices Market, by Technology - Global Hemoglobin A1c Testing Devices Market, by Geography - Recommendations - Company Profiles - ARKRAY, Inc. - Abbott Laboratories - Alere, Inc. - Bio-Rad Laboratories, Inc. - Chek Diagnostics (Polymer Technology Systems, Inc.) - Danaher Corporation (Beckman Coulter) - EKF Diagnostics Holdings plc - F. Hoffmann-La Roche Ltd. - Menarini Group - Sebia - Siemens Healthcare - Tosoh Corporation - Trinity Biotech plc For more information visit http://www.researchandmarkets.com/research/bj...globin_a1c
Global Molecular Diagnostics (Infectious Disease Testing, Blood Screening, Cancer Screening) 2014-2020 - Strategic Business Report
M2 - Wed Sep 17, 2:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w9ktnt/molecular) has announced the addition of the "Molecular Diagnostics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Molecular Diagnostics in US$ Thousands by the following Applications: Infectious Disease Testing, Blood Screening, Cancer Screening, and Other Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 165 companies including many key and niche players such as: - Abbott Laboratories - Becton, Dickinson and Company - bioM?rieux SA - Cepheid - CytoCore Inc. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Medical Diagnostics Market A Review 3. Molecular Diagnostics Industry An Overview 4. An Insight Into Applications Of Molecular Diagnostics 5. Competitive Dynamics In The Molecular Diagnostics Market 6. Product & Technology Overview 7. Product Approvals/Introductions 8. Recent Industry Activity 9. Focus On Select Players 10. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 165 (including Divisions/Subsidiaries 179) - The United States (113) - Canada (3) - Japan (1) - Europe (50) - France (7) - Germany (11) - The United Kingdom (12) - Italy (2) - Spain (1) - Rest of Europe (17) - Asia-Pacific (Excluding Japan) (11) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/w9ktnt/molecular
Research and Markets: Global Companion Diagnostics Market 2014-2019: Roche Diagnostics, Abbott Laboratories, Agilent Technologies, QIAGEN N.V. & Thermo Fisher Scientific Dominate with 86% Market Share
Business Wire - Tue Sep 16, 10:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rcg9gj/companion) has announced the addition of the "Companion Diagnostics Market byTechnology, Application , & by End-user - Global Trends & Forecasts to 2019" report to their offering.
Abbott Laboratories Has Returned 9.9% Since SmarTrend Recommendation (ABT)
Comtex SmarTrend(R) - Tue Sep 16, 9:18AM CDT
SmarTrend identified an Uptrend for Abbott Laboratories (NYSE:ABT) on April 22nd, 2014 at $38.75. In approximately 5 months, Abbott Laboratories has returned 9.89% as of today's recent price of $42.58.
Global Companion Diagnostics Market 2014-2019: Roche Diagnostics, Abbott Laboratories, Agilent Technologies, QIAGEN N.V. & Thermo Fisher Scientific Dominate with 86% Market Share
M2 - Tue Sep 16, 9:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8dnfmg/companion) has announced the addition of the "Companion Diagnostics Market byTechnology, Application , & by End-user - Global Trends & Forecasts to 2019" report to their offering. The global companion diagnostics market is expected to reach $8,730.7 million by 2019 from $3,136.9 million in 2014, growing at a CAGR of 22.7% during the forecast period (2014 to 2019). This market is segmented by technology, application, and end user. Technologies are further subsegmented into immunohistochemistry, in situ hybridization (fluoroscent ISH and chromogenic ISH), polymerase chain reaction (PCR), and next-generation sequencing (NGS)-based tests. The application market is further subsegmented into breast cancer, lung cancer, melanoma cancer, and colorectal cancer. The end users are majorly segmented into pharmaceutical companies and reference laboratories. Among technologies, the polymerase chain reaction (PCR)-based test accounted for the largest share of 65.5% in 2013. The growth of companion diagnostic in the other application segments (neurological diseases, infectious diseases, ovarian cancer, and leukemia) is expected to grow at a CAGR of 30.3%; whereas, on the basis of end user, reference laboratories is expected to grow at the fastest rate in the market. The major application driving the global companion diagnostics market is the adoption of companion diagnostic tests in oncology for various indications and for target therapies. Currently, breast, lung colorectal, and melanoma are the major types of cancer for which FDA approved companion diagnostics are available. In addition, encouragement by regulatory bodies and acceptance of tests by end users are the prominent factors for growth of market. Notable restraining factors include varied reimbursement procedures in different regions and usage of non-validated tests for identification of biomarkers. However, advanced technologies such as next-generation sequencing and growth of companion diagnostic in prostate cancer, leukemia, ovarian cancer, Alzheimer's disease, and Parkinson's disease are likely to augment the global companion diagnostic market in the future. In 2013, Roche Diagnostics (Switzerland), Abbott Laboratories (U.S.), Agilent Technologies (U.S.), QIAGEN N.V. (Netherlands), and Thermo Fisher Scientific Inc. (U.S.) together accounted for a share of 86% of the global companion diagnostics market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Global Companion Diagnostics Market, By Applications 8 Global Companion Diagnostics Market, By Technology 9 Market, By End User 10 Global Companion Diagnostics Market, By Geography 11 Competitive Landscape 12 Company Profiles - Abbott Laboratories, Inc. - Agilent Technologies, Inc. - Biogenex Laboratories - Biom?rieux - Danaher Corporation - Ge Healthcare - Myriad Genetics, Inc. - Qiagen N.V. - Roche Diagnostics - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/8dnfmg/companion
Abbott Included In Top 10 Best Companies by Working Mother Magazine
PR Newswire - Tue Sep 16, 8:11AM CDT
Abbott's (NYSE: ABT) long-held commitment to supporting working mothers and their families was acknowledged today by Working Mother magazine. The healthcare company was named among the Top 10 companies in Working Mother's 100 Best Companies list, which commends companies for establishing a corporate culture that supports working moms. This marks the fourteenth consecutive year that Abbott has been included in the esteemed ranking.
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Tue Sep 16, 8:00AM CDT
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Abbott Laboratories (NYSE: ABT), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6496-100free.
Abbott Labs Presents Positive One-Year Data on Absorb - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 4:20PM CDT
Abbott Laboratories (ABT) announced positive one-year results from the randomized, controlled trial ABSORB II, on its drug-eluting coronary bioresorbable vascular scaffold (BVS) Absorb.
Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device
PR Newswire - Mon Sep 15, 8:30AM CDT
Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent. Absorb is the world's first drug eluting BVS and functions like a metallic stent by opening up blocked blood vessels in the heart and restoring blood flow. However, unlike a metallic stent, Absorb completely dissolves over time after doing its job. ABSORB IV is designed to enroll approximately 3,000 people with coronary artery disease, mostly in the United States.
Attunity, Ltd. (ATTU) in Focus: Stock Adds 5.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 8:18AM CDT
Attunity, Ltd. was a big mover last session, as the company saw its shares rise more than 5% on the day.
Global Cardiac POC Market 2014-2018: Key Vendors are Alere, Abbott Laboratories and Roche Diagnostics
PR Newswire Europe - Mon Sep 15, 7:12AM CDT
DUBLIN, Sept. 15, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/b2tkls/global_cardiac] has announced the addition of the "Global Cardiac POC Market 2014-2018" [http://www.researchandmarkets.com/research/b2tkls/global_cardiac] report to their offering.
ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent
PR Newswire Europe - Sun Sep 14, 10:00AM CDT
-- Abbott's Absorb Bioresorbable Vascular Scaffold (BVS) is a revolutionary medical device, used in the heart, that functions like a stent but dissolves over time
AbbVie's Humira Positive in Phase III Skin Disease Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 4:05PM CDT
AbbVie Inc.'s (ABBV) Humira met the primary endpoint in a late-stage study conducted in patients suffering from moderate-to-severe hidradenitis suppurativa.
Abbott Labs (ABT) to Repurchase Shares for $3B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 3:50PM CDT
In an effort to increase shareholder value, Abbott Laboratories' (ABT) board of directors has approved a new share repurchase program.
Trading Guidelines for J&J, Merck, Pfizer, 8 Other Drug Companies
at The Street - Fri Sep 12, 10:32AM CDT
Here are some numbers to help investors make prudent decisions when allocating cash to 11 big-cap pharmaceutical companies.
Jim Cramer's 'Mad Money' Recap: Hooray for the Federal Reserve
at The Street - Wed Sep 17, 7:08PM CDT
Now that the Fed has done the right thing on monetary policy, investors should stop worrying and start thinking about how to make more money, Cramer says.
Look for Shares of Abbott Laboratories to Potentially Pullback after Yesterday's 1.12% Rise
Comtex SmarTrend(R) - Wed Sep 17, 4:27PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $42.76 to a high of $43.57. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $42.97 on volume of 4.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Abbott Labs (ABT) to Initiate New Trial on Absorb - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 4:05PM CDT
Abbott Labs (ABT) recently announced that it will initiate a trial, ABSORB IV, on bioresorbable vascular scaffold (BVS) Absorb.
Global Hemoglobin A1c Testing Devices (Laboratory Testing Devices & POC testing Devices) Market Analysis 2013-2019
M2 - Wed Sep 17, 3:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjh9n8/hemoglobin_a1c) has announced the addition of the "Hemoglobin A1c Testing Devices Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. 'Testing the levels of glycated hemoglobin provides an assurance to the healthcare practitioner about the patient's blood glucose level. This test can be used for diagnosis and monitoring of hemoglobin A1c levels in diabetic patients. Since A1C test reflects the average amount of glucose for the past 2 to 3 months, it is opined to be more reliable than conventional blood glucose test. Physicians are increasingly prescribing HbA1c test to their patients which will lead to an increase in the test volume. Moreover, rising diabetes incidence rate is a major driver for the HbA1c testing market. With growing awareness about prevention and management of diabetes, the demand for HbA1c testing devices will rise rapidly especially in the Asia-Pacific, Latin America, MiddleEast and African regions. Moreover, advent of these devices for the diagnosis of diabetes will further bolster the demand for these devices in future. For instance, approval for the COBAS INTEGRA 800 Tina-quant HbA1cDx assay, in 2013and Abbott's ARCHITECT Clinical Chemistry Hemoglobin A1c (HbA1c) test approved in 2014 for the diagnosis of diabetes were the major steps in the hemoglobin A1c testing industry. With this diagnostic tools, physicians can combat the rising incidence of diabetes with timely and appropriate actions in identifying and managing diabetes. Based on the end-use, the global hemoglobin A1c testing devices market is categorized into two segments namely laboratory testing and point-of-care (POC) testing devices. Laboratory testing devices held the majority share of the market in 2012, while the global market for point-of-care testing devices is expected to grow at a faster paceduring the forecast period. Based on technologies, the hemoglobin A1c testing devices market is further categorized into five segments, namely, ion-exchange HPLC, immunoassay, boronate affinity chromatography, direct enzymatic assay and others. The boronate affinity chromatography market will be growing at a faster pace during the forecast period as this technology has no interference from hemoglobin variants and is also used in both laboratory as well as point-of-care testing. Healthcare practitioners are recommending the use of devices which offer least variant interference and this would elevate the demand for boronate affinity chromatography in HbA1c testing. The global hemoglobin A1c testing devices market is categorized into the following segments: Hemoglobin A1cTesting Devices Market, by End-use - Laboratory Testing Devices - Point-of-Care (POC)Testing Devices Hemoglobin A1cTesting Devices Market, by Technology - Ion-Exchange High Performance Liquid Chromatography (HPLC) - Immunoassay - Boronate Affinity Chromatography - Direct Enzymatic Assay - Others (Micro-Optical Detection Method and Capillary Electrophoresis) Key Topics Covered: - Introduction - Executive Summary - Global Hemoglobin A1c Testing Devices Market Overview - Global Hemoglobin A1c Testing Devices Market, by End-Use - Global Hemoglobin A1c Testing Devices Market, by Technology - Global Hemoglobin A1c Testing Devices Market, by Geography - Recommendations - Company Profiles - ARKRAY, Inc. - Abbott Laboratories - Alere, Inc. - Bio-Rad Laboratories, Inc. - Chek Diagnostics (Polymer Technology Systems, Inc.) - Danaher Corporation (Beckman Coulter) - EKF Diagnostics Holdings plc - F. Hoffmann-La Roche Ltd. - Menarini Group - Sebia - Siemens Healthcare - Tosoh Corporation - Trinity Biotech plc For more information visit http://www.researchandmarkets.com/research/bj...globin_a1c
Global Molecular Diagnostics (Infectious Disease Testing, Blood Screening, Cancer Screening) 2014-2020 - Strategic Business Report
M2 - Wed Sep 17, 2:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w9ktnt/molecular) has announced the addition of the "Molecular Diagnostics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Molecular Diagnostics in US$ Thousands by the following Applications: Infectious Disease Testing, Blood Screening, Cancer Screening, and Other Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 165 companies including many key and niche players such as: - Abbott Laboratories - Becton, Dickinson and Company - bioM?rieux SA - Cepheid - CytoCore Inc. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Medical Diagnostics Market A Review 3. Molecular Diagnostics Industry An Overview 4. An Insight Into Applications Of Molecular Diagnostics 5. Competitive Dynamics In The Molecular Diagnostics Market 6. Product & Technology Overview 7. Product Approvals/Introductions 8. Recent Industry Activity 9. Focus On Select Players 10. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 165 (including Divisions/Subsidiaries 179) - The United States (113) - Canada (3) - Japan (1) - Europe (50) - France (7) - Germany (11) - The United Kingdom (12) - Italy (2) - Spain (1) - Rest of Europe (17) - Asia-Pacific (Excluding Japan) (11) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/w9ktnt/molecular
Research and Markets: Global Companion Diagnostics Market 2014-2019: Roche Diagnostics, Abbott Laboratories, Agilent Technologies, QIAGEN N.V. & Thermo Fisher Scientific Dominate with 86% Market Share
Business Wire - Tue Sep 16, 10:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rcg9gj/companion) has announced the addition of the "Companion Diagnostics Market byTechnology, Application , & by End-user - Global Trends & Forecasts to 2019" report to their offering.
Abbott Laboratories Has Returned 9.9% Since SmarTrend Recommendation (ABT)
Comtex SmarTrend(R) - Tue Sep 16, 9:18AM CDT
SmarTrend identified an Uptrend for Abbott Laboratories (NYSE:ABT) on April 22nd, 2014 at $38.75. In approximately 5 months, Abbott Laboratories has returned 9.89% as of today's recent price of $42.58.
Global Companion Diagnostics Market 2014-2019: Roche Diagnostics, Abbott Laboratories, Agilent Technologies, QIAGEN N.V. & Thermo Fisher Scientific Dominate with 86% Market Share
M2 - Tue Sep 16, 9:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8dnfmg/companion) has announced the addition of the "Companion Diagnostics Market byTechnology, Application , & by End-user - Global Trends & Forecasts to 2019" report to their offering. The global companion diagnostics market is expected to reach $8,730.7 million by 2019 from $3,136.9 million in 2014, growing at a CAGR of 22.7% during the forecast period (2014 to 2019). This market is segmented by technology, application, and end user. Technologies are further subsegmented into immunohistochemistry, in situ hybridization (fluoroscent ISH and chromogenic ISH), polymerase chain reaction (PCR), and next-generation sequencing (NGS)-based tests. The application market is further subsegmented into breast cancer, lung cancer, melanoma cancer, and colorectal cancer. The end users are majorly segmented into pharmaceutical companies and reference laboratories. Among technologies, the polymerase chain reaction (PCR)-based test accounted for the largest share of 65.5% in 2013. The growth of companion diagnostic in the other application segments (neurological diseases, infectious diseases, ovarian cancer, and leukemia) is expected to grow at a CAGR of 30.3%; whereas, on the basis of end user, reference laboratories is expected to grow at the fastest rate in the market. The major application driving the global companion diagnostics market is the adoption of companion diagnostic tests in oncology for various indications and for target therapies. Currently, breast, lung colorectal, and melanoma are the major types of cancer for which FDA approved companion diagnostics are available. In addition, encouragement by regulatory bodies and acceptance of tests by end users are the prominent factors for growth of market. Notable restraining factors include varied reimbursement procedures in different regions and usage of non-validated tests for identification of biomarkers. However, advanced technologies such as next-generation sequencing and growth of companion diagnostic in prostate cancer, leukemia, ovarian cancer, Alzheimer's disease, and Parkinson's disease are likely to augment the global companion diagnostic market in the future. In 2013, Roche Diagnostics (Switzerland), Abbott Laboratories (U.S.), Agilent Technologies (U.S.), QIAGEN N.V. (Netherlands), and Thermo Fisher Scientific Inc. (U.S.) together accounted for a share of 86% of the global companion diagnostics market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Global Companion Diagnostics Market, By Applications 8 Global Companion Diagnostics Market, By Technology 9 Market, By End User 10 Global Companion Diagnostics Market, By Geography 11 Competitive Landscape 12 Company Profiles - Abbott Laboratories, Inc. - Agilent Technologies, Inc. - Biogenex Laboratories - Biom?rieux - Danaher Corporation - Ge Healthcare - Myriad Genetics, Inc. - Qiagen N.V. - Roche Diagnostics - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/8dnfmg/companion
Abbott Included In Top 10 Best Companies by Working Mother Magazine
PR Newswire - Tue Sep 16, 8:11AM CDT
Abbott's (NYSE: ABT) long-held commitment to supporting working mothers and their families was acknowledged today by Working Mother magazine. The healthcare company was named among the Top 10 companies in Working Mother's 100 Best Companies list, which commends companies for establishing a corporate culture that supports working moms. This marks the fourteenth consecutive year that Abbott has been included in the esteemed ranking.
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Tue Sep 16, 8:00AM CDT
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Abbott Laboratories (NYSE: ABT), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6496-100free.
Abbott Labs Presents Positive One-Year Data on Absorb - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 4:20PM CDT
Abbott Laboratories (ABT) announced positive one-year results from the randomized, controlled trial ABSORB II, on its drug-eluting coronary bioresorbable vascular scaffold (BVS) Absorb.
Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device
PR Newswire - Mon Sep 15, 8:30AM CDT
Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent. Absorb is the world's first drug eluting BVS and functions like a metallic stent by opening up blocked blood vessels in the heart and restoring blood flow. However, unlike a metallic stent, Absorb completely dissolves over time after doing its job. ABSORB IV is designed to enroll approximately 3,000 people with coronary artery disease, mostly in the United States.
Attunity, Ltd. (ATTU) in Focus: Stock Adds 5.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 8:18AM CDT
Attunity, Ltd. was a big mover last session, as the company saw its shares rise more than 5% on the day.
Global Cardiac POC Market 2014-2018: Key Vendors are Alere, Abbott Laboratories and Roche Diagnostics
PR Newswire Europe - Mon Sep 15, 7:12AM CDT
DUBLIN, Sept. 15, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/b2tkls/global_cardiac] has announced the addition of the "Global Cardiac POC Market 2014-2018" [http://www.researchandmarkets.com/research/b2tkls/global_cardiac] report to their offering.
ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent
PR Newswire Europe - Sun Sep 14, 10:00AM CDT
-- Abbott's Absorb Bioresorbable Vascular Scaffold (BVS) is a revolutionary medical device, used in the heart, that functions like a stent but dissolves over time
AbbVie's Humira Positive in Phase III Skin Disease Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 4:05PM CDT
AbbVie Inc.'s (ABBV) Humira met the primary endpoint in a late-stage study conducted in patients suffering from moderate-to-severe hidradenitis suppurativa.
Abbott Labs (ABT) to Repurchase Shares for $3B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 3:50PM CDT
In an effort to increase shareholder value, Abbott Laboratories' (ABT) board of directors has approved a new share repurchase program.
Trading Guidelines for J&J, Merck, Pfizer, 8 Other Drug Companies
at The Street - Fri Sep 12, 10:32AM CDT
Here are some numbers to help investors make prudent decisions when allocating cash to 11 big-cap pharmaceutical companies.
(0)
(0)